Dydrogesterone – a promising asset for luteal phase support in infertility treatment

Written By: user

IJCP Editorial Team

Published On: 08 Feb, 2024 12:39 PM | Updated On: 08 Feb, 2024 12:54 PM

Dydrogesterone – a promising asset for luteal phase support in infertility treatment

A randomized, controlled, comparative study conducted from 2022-2023 at Gandhi Hospital evaluated the efficacy of oral dydrogesterone versus oral sustained-release micronized hydroxyprogesterone for luteal phase support.

This study enrolled 200 women aged 18-40 years who were attending the infertility outpatient department.

The findings revealed that oral dydrogesterone outperformed sustained-release micronized hydroxyprogesterone, with positive pregnancy test rates of 83% and 30%, respectively. The oral administration of dydrogesterone was well-tolerated and demonstrated a safety profile similar to sustained-release micronized hydroxyprogesterone.

The results highlighted the effectiveness of dydrogesterone over sustained-release micronized hydroxyprogesterone for luteal phase support in infertility treatment. Dydrogesterone exhibited superior positive pregnancy rates, making it a commendable choice in reproductive medicine.

The unique pharmacological attributes of dydrogesterone, devoid of estrogenic, androgenic, or glucocorticoid effects, emphasize its suitability for assisted reproduction. The authors stated that dydrogesterone is a promising asset in enhancing successful outcomes in infertility treatment – suggesting its consideration as a valuable adjunctive therapy during the luteal phase.

Source: Vellanki J, Sravani E. Indian J ObstetGynecol Res. 2023;10(4):456-459

IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.